Loading patent…
AssigneeNanjing GenScript Biotech Co., Ltd.
InventorsZhongdao Li, Liusong Yin, Zhenyu Liu, Tielin Zhou, Zhuo Fang
Estimating the term…
Provided are a monoclonal antibody-cytokine fusion protein dimer and an application thereof. The monoclonal antibody comprises two heavy chains, the fusion protein dimer comprises a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein one heavy chain of the monoclonal antibody is connected to a cytokine to form the first heavy chain polypeptide chain, and the other heavy chain of the monoclonal antibody is optionally connected to another cytokine to form the second heavy chain polypeptide chain. The monoclonal antibody-cytokine fusion protein dimer provided not only fully retains the biological activity of the antibody, but also significantly improves the biological activity of the cytokine(s). More importantly, by using the target specificity of the antibody molecule, the immune response of immune cells is enhanced and the toxicity of the cytokine(s) is reduced, and thus, on the premise of enhancing the efficacy of the drug, the safety of the medication is ensured.
A monoclonal antibody-cytokine fusion protein dimer, wherein the monoclonal antibody comprises two heavy chains and two associated light chains, the fusion protein dimer comprises a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein one heavy chain of the monoclonal antibody is connected with a cytokine to form the first heavy chain polypeptide chain, and the other heavy chain of the monoclonal antibody is connected with another cytokine to form the second heavy chain polypeptide chain, wherein the monoclonal antibody is a full-length anti-PD-1 antibody, wherein the associated light chains each comprise the amino acid sequence of SEQ ID NO:52, and wherein:
Dependencies are inferred from the claim text.